AstraZeneca India breast cancer drug lynparza gets DCGI okay
AstraZeneca India, a science-led biopharmaceutical company, has announced that it has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer, who have previously been treated with neoadjuvant or adjuvant...
AstraZeneca India, a science-led biopharmaceutical company, has announced that it has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy.
The approval was based on results from the OlympiA Phase III trial, which suggested that Olaparib demonstrated a statistically significant and clinically meaningful improvement, with an overall survival benefit. With the DCGI's approval, Lynparza is now approved in the US, EU, Japan, India and several other countries for the treatment of the same. Currently, Lynparza is the first and only approved medicine targeting BRCA mutations in early-stage breast cancer.
For more details check out the link given below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd